Back to search

University of Leeds

Diagnosis and management of early inflammatory arthritis

Abstract

dc:description.abstract

Rheumatoid arthritis (RA) represents a disease continuum from the pre-clinical period, through undifferentiated inflammatory arthritis (IA) to early then established RA. Improved patient outcomes in recent years reflect early diagnosis, prompt disease-modifying anti-rheumatic drug (DMARD) therapy, treat-to-target strategies and use of biological therapies (bDMARDs) particularly following failure of conventional synthetic therapies (csDMARDs). Optimal use of bDMARDs in early disease, however, has not been established. Early detection in the pre-clinical stage is potentially achievable with modern diagnostics but understanding of how to use these biomarkers is lacking. A systematic literature review on the use of bDMARDs was performed and confirmed the efficacy of bDMARDs in patients with established RA. Few studies were found addressing their use in early disease. Two randomised controlled trials were performed to explore early bDMARD intervention. The first, in early DMARD-naïve RA, compared methotrexate and infliximab to methotrexate and high-dose intravenous methylprednisolone as induction therapy, followed by a treat-to-target strategy; both arms demonstrated efficacy with no significant between-group differences. In the second, early DMARD naïve IA patients treated with combination etanercept and methotrexate had earlier clinical improvement than methotrexate monotherapy; however both groups achieved good 12 month outcomes. In a longitudinal cohort study conducted in secondary care, 50% of patients with musculoskeletal (MSK) symptoms and anti-cyclic citrullinated peptide (anti-CCP) antibodies progressed to clinical IA. Use of additional biomarkers including rheumatoid factor, shared epitope and ultrasound enabled further risk stratification for progression. In a primary care cohort, the anti-CCP antibody was positive in 2.8% with new nonspecific MSK symptoms with almost half progressing to IA. In summary, in early DMARD naïve IA, use of bDMARD may not be superior to csDMARDs with a treat-to-target approach. In patients with MSK symptoms, anti-CCP testing identifies individuals at risk of developing IA; additional biomarkers improve prediction and are feasible for clinical use.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2015

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Nam, Jacqueline Leong
Advisors dc:contributor.advisor
  • Conaghan, Philip
  • Emery, Paul

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.675526
Dc Identifier Grantnumber
Eudract-2005-005013-37; ISRCTN48638981 (http://www.controlled-trials.com/ISRCTN48638981/idea).
Eudract-2005-005467-29; ISRCTN 55428162 (http://www.controlled-trials.com/ISRCTN55428162/EMPIRE)
NCT02012764 at ClinicalTrials.gov.

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Nam, Jacqueline Leong. Diagnosis and management of early inflammatory arthritis. doctoral thesis, University of Leeds, 2015.